02 Mar 2011
Correction: Director/PDMR Shareholding
The announcement released yesterday, advising of the awards granted under The Shire Portfolio Share Plan to the Company’s Executive Directors and PDMRs, reflected the incorrect number of ADSs granted to Mr Angus Russell, Chief Executive Officer of the Company.
The Stock Appreciation Right Award granted to Mr Russell was over 63,126 ADSs and not 63,015 ADSs. In addition, the Performance Share Award granted to Mr Russell was over 47,344 ADSs and not 47,262 ADSs.
March 2, 2011 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that on February 28, 2011 the following Persons Discharging Managerial Responsibility ("PDMRs") were granted awards under the Shire Portfolio Share Plan (the "Plan").
Awards of Stock Appreciation Rights ("SARs") under Part A of the Plan
|Name of PDMR||Type of Security||No of Ordinary Shares or ADSs||Exercise price|
|Angus Russell (Chief Executive Officer)*||ADSs||63,126||$83.79|
|Graham Hetherington (Chief Financial Officer)*||Ordinary Shares||82,873||£17.23|
|Tatjana May||Ordinary Shares||28,379||£17.23|
SARs will normally vest after three years, subject to any performance targets having been satisfied. Vested SARs will be capable of exercise for a period of four years. No consideration was paid for the grant of the SARs.
Performance Share Awards ("PSA Awards") under Part B of the Plan
|Name of PDMR||Type of Security||No of Ordinary Shares or ADSs||Market Value|
|Angus Russell (Chief Executive Officer)*||ADSs||47,344||$83.79|
|Graham Hetherington (Chief Financial Officer)*||Ordinary Shares||60,769||£17.23|
|Tatjana May||Ordinary Shares||20,433||£17.23|
The PSA Awards will normally vest after three years, subject to any performance targets having been satisfied. Once vested, sufficient ordinary shares or ADSs will be transferred or allotted to the participant within 30 days. No consideration was paid for the grant of the PSA Awards.
This notification is made to satisfy the Company's obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Deputy Company Secretary
For further information please contact:
|Eric Rojasemail@example.com||+1 781 482 0999|
Notes to editors
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.